SCHEDULE: Invus Group Discloses 5.1% Stake in Olema Pharmaceuticals

Raymond Debbane and affiliated entities, including Invus Public Equities, report a combined beneficial ownership of 5.1% in Olema Pharmaceuticals, Inc.

Summary

• Raymond Debbane and affiliated entities, including Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, and Ulys, L.L.C., have filed a Schedule 13G regarding Olema Pharmaceuticals, Inc.
• The filing discloses beneficial ownership of common stock in Olema Pharmaceuticals, Inc., par value $0.0001 per share.
• Raymond Debbane is reported as beneficially owning 4,461,949 shares, representing 5.1% of the company's common stock.
• Invus Public Equities, L.P. directly holds 3,898,500 shares, accounting for 4.5% of the class.
• Avicenna Life Sci Master Fund LP directly holds 563,449 shares, accounting for 0.6% of the class.
• The percentage calculations are based on 87,156,961 shares outstanding as of March 11, 2026, as reported by the Issuer in its annual report on Form 10-K filed on March 16, 2026.
• The Reporting Persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as Schedule 13G reports are routine disclosures of beneficial ownership and do not inherently convey positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can sometimes signal long-term investor confidence in a company within the biotechnology sector, though this filing itself does not provide strategic insights.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing investor perception of stability or institutional interest.

Key Dates

Keywords

Olema Pharmaceuticals, Invus Public Equities, Raymond Debbane, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, Biotechnology, Pharmaceuticals